Development of a virus-mimicking nanocarrier for drug delivery systems: The bio-nanocapsule

被引:46
作者
Somiya, Masaharu [1 ,2 ,3 ]
Kuroda, Shun'ichi [1 ,2 ]
机构
[1] Osaka Univ, Inst Sci & Ind Res, Ibaraki, Osaka 5670047, Japan
[2] Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan
[3] Japan Soc Promot Sci, Tokyo 1020083, Japan
关键词
Active targeting; Biomimicking; Hepatitis B virus; Liposome; Membrane fusion; Virus-like particle; HEPATITIS-B-VIRUS; L-PROTEIN PARTICLES; IN-VIVO; INTRACELLULAR TRAFFICKING; CAPSID PROTEINS; GENE-REGULATION; SIRNA; NANOPARTICLES; LIPOSOMES; CELLS;
D O I
10.1016/j.addr.2015.10.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
As drug delivery systems, nanocarriers should be capable of executing the following functions: evasion of the host immune system, targeting to the diseased site, entering cells, escaping from endosomes, and releasing payloads into the cytoplasm. Since viruses perform some or all of these functions, they are considered naturally occurring nanocarriers. To achieve biomimicry of the hepatitis B virus (HBV), we generated the "bio-nanocapsule" (BNC)-which deploys the human hepatocyte-targeting domain, fusogenic domain, and polymerized-albumin receptor domain of HBV envelope L protein on its surface-by overexpressing the L protein in yeast cells. BNCs are capable of delivering various payloads to the cytoplasm of human hepatic cells specifically in vivo, which is achieved via formation of complexes with various materials (e.g., drugs, nucleic acids, and proteins) by electroporation, fusion with liposomes, or chemical modification. In this review, we describe BNC-related technology, discuss retargeting strategies for BNCs, and outline other virus-inspired nanocarriers. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:77 / 89
页数:13
相关论文
共 111 条
  • [1] Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis
    Akinc, A
    Thomas, M
    Klibanov, AM
    Langer, R
    [J]. JOURNAL OF GENE MEDICINE, 2005, 7 (05) : 657 - 663
  • [2] ALMEIDA JD, 1975, LANCET, V2, P899
  • [3] An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells
    Ara, Mst Naznin
    Matsuda, Takashi
    Hyodo, Mamoru
    Sakurai, Yu
    Hatakeyama, Hiroto
    Ohga, Noritaka
    Hida, Kyoko
    Harashima, Hideyoshi
    [J]. BIOMATERIALS, 2014, 35 (25) : 7110 - 7120
  • [4] Doxil® - The first FDA-approved nano-drug: Lessons learned
    Barenholz, Yechezkel
    [J]. JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) : 117 - 134
  • [5] Entry of hepatitis B and C viruses - recent progress and future impact
    Baumert, Thomas F.
    Meredith, Luke
    Ni, Yi
    Felmlee, Daniel J.
    McKeating, Jane A.
    Urban, Stephan
    [J]. CURRENT OPINION IN VIROLOGY, 2014, 4 : 58 - 65
  • [6] Functions of cell surface heparan sulfate proteoglycans
    Bernfield, M
    Götte, M
    Park, PW
    Reizes, O
    Fitzgerald, ML
    Lincecum, J
    Zako, M
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1999, 68 : 729 - 777
  • [7] A VERSATILE VECTOR FOR GENE AND OLIGONUCLEOTIDE TRANSFER INTO CELLS IN CULTURE AND IN-VIVO - POLYETHYLENIMINE
    BOUSSIF, O
    LEZOUALCH, F
    ZANTA, MA
    MERGNY, MD
    SCHERMAN, D
    DEMENEIX, B
    BEHR, JP
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (16) : 7297 - 7301
  • [8] Nanoparticle and targeted systems for cancer therapy
    Brannon-Peppas, Lisa
    Blanchette, James O.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2012, 64 : 206 - 212
  • [9] Progress of drug-loaded polymeric micelles into clinical studies
    Cabral, Horacio
    Kataoka, Kazunori
    [J]. JOURNAL OF CONTROLLED RELEASE, 2014, 190 : 465 - 476
  • [10] COSSART YE, 1970, LANCET, V1, P848